Gilead’s twice-yearly lenacapavir shows promise in HIV prevention trial

Gilead’s twice-yearly lenacapavir shows promise in HIV prevention trial

Submitted by admin on December 1, 2024 - 11:46am
Source: 
Clinical Trials Arena
News Tags: 
Gilead Sciences
clinical trials
lenacapavir
HIV
PrEP
Headline: 
Gilead’s twice-yearly lenacapavir shows promise in HIV prevention trial
snippet: 

The Phase III Purpose 2 trial compared the safety and efficacy of twice-yearly subcutaneous lenacapavir for pre-exposure prophylaxis (PrEP) against once-daily oral Truvada.

Do Not Allow Advertisers to Use My Personal information